Walter, I. and Schulz, U. and Vogelhuber, M. and Wiedmann, K. and Endlicher, E. and Klebl, F. and Andreesen, R. and Herr, W. and Ghibelli, L. and Hackl, C. and Wiest, R. and Reichle, A. (2017) Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial. MEDICAL ONCOLOGY, 34 (12): 192. ISSN 1357-0560, 1559-131X
Full text not available from this repository. (Request a copy)Abstract
Systemic therapy for advanced hepatocellular carcinoma (HCC) is still challenging. A biomodulatory therapy approach targeting the communicative infrastructure of HCC, including metronomic low-dose chemotherapy with capecitabine, pioglitazone and rofecoxib, has been evaluated in patients with non-curative HCC. Altogether 38 patients were evaluable in this one-arm, multicenter phase II trial. The primary endpoint, median progression-free survival was 2.7 months (95% CI: 1.6-3.79) for all evaluable patients and 8.4 months (95% CI: 0-18.13) for patients ae<yen> 6 weeks on protocol. Median overall survival (OS) was 6.7 months (95% CI: 4.08-9.31) and 9.4 months (95% CI: 4.82-13.97), respectively. Most common adverse events were edemas grade 3, which were commonly related to the advanced stage, with 66% of the patients suffering from liver cirrhosis. Exploratory data analyses showed significant impact of ECOG performance status grade 0 versus 1 and CLIP score 0/1 versus > 1 on OS, 9.8 months (95% CI: 4.24-15.35) versus 2.7 months (95% CI: 1.03-4.36; P = 0.002), and 9.8 months (95% CI: 3.23-16.37) versus 4.4 months (95% CI: 3.14-5.66; P = 0.009), respectively. Preceding tumor surgery had significant beneficial impact on survival, as well as maximal tumor diameter of < 5 cm. The correlation of C-reactive protein decrease with significantly improved OS underlines the close link between inflammation and tumor control. Biomodulatory therapy in advanced HCC may be a low toxic, efficacious treatment and principally demonstrates that such approaches should be followed further for treatment of advanced HCC.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ACTIVATED RECEPTOR-GAMMA; C-REACTIVE PROTEIN; THERAPEUTIC TARGET; SIGNALING PATHWAY; CLINICAL-TRIALS; CELL-GROWTH; IN-VITRO; EXPRESSION; CANCER; HEPATOCARCINOGENESIS; Hepatocellular carcinoma; Biomodulatory therapy; COX-2 inhibitor; Pioglitazone; Metronomic low-dose chemotherapy; Anakoinosis |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Chirurgie Medicine > Lehrstuhl für Innere Medizin I Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Dec 2018 13:19 |
| Last Modified: | 01 Mar 2019 07:58 |
| URI: | https://pred.uni-regensburg.de/id/eprint/1871 |
Actions (login required)
 |
View Item |
